Check The Patient Information Leaflet Or Speak To A Clinician Guidance can vary depending on your current dose and how long you have been on treatment
New England Journal of Medicine, 381(9), 841-851
But semaglutide does more than just curb appetite
Medical Research Archives, [online] 13(1)
According to incomplete statistics, sales of Novo Nordisk's semaglutide have been soaring year after year, with 2023 sales surpassing $21.2 billion, making it the first GLP-1 drug to join the "billion-dollar club." Its market position is quickly catching up with Merck's Keytruda, and it has the potential to become the next "blockbuster" drug
FDA Accepts NDA Submission for Oral Semaglutide 25 mg The FDA accepted the NDA for oral semaglutide 25 mg, a potentially revolutionary daily treatment for weight management and cardiovascular risk reduction